Skip to main content
Download PDF

Immune therapy in autism: Historical experience and future directions with immunomodulatory therapy

Neurotherapeutics volume 7, pages 293–301 (2010)Cite this article

Summary

Autism affects 1 in 110 new births, and it has no single etiology with uniform agreement. This has a significant impact on the quality of life for individuals who have been diagnosed with autism. Although autism has a spectrum quality with a shared diagnosis, it presents a uniquely different clinical appearance in each individual. Recent research of suspected immunological factors have provided more support for a probable immunological process or for processes that may play a role in the acquisition of an autistic condition. These factors include prenatal, genetic, and postnatal findings, as well as the discovery of a dysfunctional chronic pro-inflammatory state in brain tissue and cerebrospinal fluid in subsets of autistic patients. These findings offer new theories that may lead to the development of disease modification or preventative therapeutic options in the near future. This article reviews prenatal, genetic, and observed immune aspects of the autism condition that may be risk factors in the presentation of the autistic clinical phenotype. Historical immune interventions in autism are reviewed and potential new therapies and interventions are discussed.

References

  1. Rice C. Prevalence of autism spectrum disorders. Autism and Developmental Disabilities Monitoring Network, United States, 2006. MMWR 2009;58;1.

    Google Scholar 

  2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision. Washington, DC: Skyscape, 1994.

    Google Scholar 

  3. Shattuck PT. The contribution of diagnostic substitution to the growing administrative prevalence of autism in US special education. Pediatrics 2006;117: 1028–1037.

    Article  PubMed  Google Scholar 

  4. Department of Developmental Services. Autistic spectrum disorders: changes in the California caseload: an update 1999–2002. Sacramento, CA: State of California; 2003.

  5. Croen LA, Grether JK, Hoogstrate J, et al. The changing prevalence of autism in California. J Autism Dev Disord 2002;32: 207–215.

    Article  PubMed  Google Scholar 

  6. Institute MIND. Report to the legislature on the principle findings from the epidemiology of autism in California. Sacramento, CA: University of California, Davis, 2002.

    Google Scholar 

  7. Chez MG, Chang M, Krasne V, et al. Frequency of epileptiform EEG abnormalities in a sequential screening of autistic patients with no known clinical epilepsy from 1996 to 2005. Epilepsy Behav 2006;8: 267–271.

    Article  PubMed  Google Scholar 

  8. Olsson I, Steffenburg S, Gillberg C. Epilepsy in autism and autisticlike conditions. A population-based study. Arch Neurol 1988;45: 666–668.

    CAS  PubMed  Google Scholar 

  9. Spence SJ. The genetics of autism. Semin Pediatr Neurol 2004;11: 196–204.

    Article  PubMed  Google Scholar 

  10. Wassink TH, Piven J, Patil SR. Chromosomal abnormalities in a clinic sample of individuals with autistic disorder. Psychiatr Genet 2001;11: 57–63.

    CAS  Article  PubMed  Google Scholar 

  11. Campbell DB, Sutcliffe JS, Ebert PJ, et al. A genetic variant that disrupts MET transcription is associated with autism. Proc Natl Acad Sci U S A 2006;103: 16834–16839.

    CAS  Article  PubMed  Google Scholar 

  12. Patterson P. Pregnancy, immunity, schizophrenia, and autism. Eng Sci 2006;69: 10–21.

    Google Scholar 

  13. Connolly AM, Chez MG, Pestronk A, et al. Serum auto-antibodies to brain in Landau-Kleffner variant, autism, and other neurologic disorders. J Pediatr 1999;134: 607–613.

    CAS  Article  PubMed  Google Scholar 

  14. Nelson KB, Grether JK, Croen LA, et al. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann Neurol 2001;49: 597–606.

    CAS  Article  PubMed  Google Scholar 

  15. Pardo CA, Vargas DL, Zimmerman AW. Immunity, neuroglia and neuroinflammation in autism. Int Rev Psychiatry 2005;17: 485–495.

    Article  PubMed  Google Scholar 

  16. Todd RD, Hickok JM, Anderson GM, et al. Antibrain antibodies in infantile autism. Biol Psychiatry 1988;23: 644–647.

    CAS  Article  PubMed  Google Scholar 

  17. Vargas DL, Nascimbene C, Krishnan C, et al. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 2005;57: 67–81.

    CAS  Article  PubMed  Google Scholar 

  18. Atladottir HO, Pedersen MG, Thorsen P, et al. Association of family history of autoimmune diseases and autism spectrum disorders. Pediatrics 2009;124: 687–694.

    Article  PubMed  Google Scholar 

  19. Comi AM, Zimmerman AW, Frye VH, et al. Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism. J Child Neurol 1999;14: 388–394.

    CAS  Article  PubMed  Google Scholar 

  20. Daniels WW, Warren RP, Odell JD, et al. Increased frequency of the extended or ancestral haplotype B44-SC30-DR4 in autism. Neuropsychobiology 1995;32: 120–123.

    CAS  Article  PubMed  Google Scholar 

  21. Warren RP, Margaretten NC, Pace NC, et al. Immune abnormalities in patients with autism. J Autism Dev Disord 1986;16: 189–197.

    CAS  Article  PubMed  Google Scholar 

  22. Connolly AM. Brain-derived neurotrophic factor and auto-antibodies to neural antigens in sera of children with autistic spectrum disorders, Landau-Kleffner syndrome, and epilepsy. Biol Psychiat 2006;59: 354–363.

    CAS  Article  PubMed  Google Scholar 

  23. Singh VK, Lin SX, Yang VC. Serological association of measles virus and human herpesvirus-6 with brain auto-antibodies in autism. Clin Immunol Immunopathol 1998;89: 105–108.

    CAS  Article  PubMed  Google Scholar 

  24. Singh VK, Warren RP, Odell JD, et al. Antibodies to myelin basic protein in children with autistic behavior. Brain Behav Immun 1993;7: 97–103.

    CAS  Article  PubMed  Google Scholar 

  25. Warren RP, Yonk LJ, Burger RA, et al. Deficiency of suppressor-inducer (CD4+CD45RA+) T cells in autism. Immunol Invest 1990;19: 245–251.

    CAS  Article  PubMed  Google Scholar 

  26. Stubbs EG, Crawford ML. Depressed lymphocyte responsiveness in autistic children. J Autism Child Schizophr 1977;7: 49–55.

    CAS  Article  PubMed  Google Scholar 

  27. Margaretten NC, Warren RP. Reduced natural killer cell activity and OKT4/OKT8 ratio in epileptic patients. Immunol Invest 1986: 15: 159–167.

    CAS  Article  PubMed  Google Scholar 

  28. Gupta S, Aggarwal S, Heads C. Dysregulated immune system in children with autism: beneficial effects of intravenous immune globulin on autistic characteristics. J Autism Dev Disord 1996;26: 439–452.

    CAS  Article  PubMed  Google Scholar 

  29. Plioplys A. Immunoglobulin reactivity in autism and Rett’s syndrome. Dev Brain Dysfunct 1994;7: 12–16.

    Google Scholar 

  30. Zimmerman AW. Serum immunoglobulins and autoimmune profiles in children with autism. Ann Neurol 1995;38: 528.

    Google Scholar 

  31. Gupta S. Treatment of children with autism with intravenous immunoglobulin. J Child Neurol 1999;14: 203–205.

    CAS  Article  PubMed  Google Scholar 

  32. Plioplys A. Intravenous immunoglobulin treatment of children with autism. J Child Neurol 1999;13: 79–82.

    Article  Google Scholar 

  33. Risch N, Spiker D, Lotspeich L, et al. A genomic screen of autism: evidence for a multilocus etiology. Am J Hum Genet 1999;65: 493–507.

    CAS  Article  PubMed  Google Scholar 

  34. Bailey A, Le Couteur A, Gottesman I, et al. Autism as a strongly genetic disorder: evidence from a British twin study. Psychol Med 1995;25: 63–77.

    CAS  Article  PubMed  Google Scholar 

  35. Hallmayer J, Glasson EJ, Bower C, et al. On the twin risk in autism. Am J Hum Genet 2002;71: 941–946.

    Article  PubMed  Google Scholar 

  36. Steffenburg S, Gillberg C, Hellgren L, et al. A twin study of autism in Denmark, Finland, Iceland, Norway and Sweden. J Child Psychol Psych 1989;30: 405–416.

    CAS  Article  Google Scholar 

  37. Boccone L, Dessi V, Zappu A, et al. Bannayan-Riley-Ruvalcaba syndrome with reactive nodular lymphoid hyperplasia and autism and a PTEN mutation. Am J Med Genet A 2006;140: 1965–1969.

    PubMed  Google Scholar 

  38. Burger RA. Possible immunogenetic basis for autism. Ment Retard Dev D R 1998;4: 137–141.

    Article  Google Scholar 

  39. Ashwood P, Wills S, Van de Water J. The immune response in autism: a new frontier for autism research. J Leukoc Biol 2006;80: 1–15.

    CAS  Article  PubMed  Google Scholar 

  40. Shi L, Fatemi SH, Sidwell RW, et al. Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. J Neurosci 2003;23: 297–302.

    PubMed  Google Scholar 

  41. Nawa H, Takei N. Recent progress in animal modeling of immune inflammatory processes in schizophrenia: implication of specific cytokines. Neurosci Res 2006;56: 2–13.

    CAS  Article  PubMed  Google Scholar 

  42. Palmen SJ, van Engeland H, Hof PR, et al. Neuropathological findings in autism. Brain 2004;127(Pt 12): 2572–2583.

    Article  PubMed  Google Scholar 

  43. Patterson PH. Modeling features of autism in animals. Boca Raton, FL: Taylor & Francis, 2005.

    Google Scholar 

  44. Smith SE, Li J, Garbett K, et al. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 2007;27: 10695–10702.

    CAS  Article  PubMed  Google Scholar 

  45. Urakubo A, Jarskog LF, Lieberman JA, et al. Prenatal exposure to maternal infection alters cytokine expression in the placenta, amniotic fluid, and fetal brain. Schizophr Res 2001;47: 27–36.

    CAS  Article  PubMed  Google Scholar 

  46. Meyer U, Murray PJ, Urwyler A, et al. Adult behavioral and pharmacological dysfunctions following disruption of the fetal brain balance between pro-inflammatory and IL-10-mediated anti-inflammatory signaling. Mol Psychiatry 2008;13: 208–221.

    CAS  Article  PubMed  Google Scholar 

  47. Chez MG, Buchanan CP, Aimonovitch MC, et al. Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders. J Child Neurol 2002;17: 833–837.

    Article  PubMed  Google Scholar 

  48. Morris C. Fetal anti-brain anti-bodies in serum of mothers of children with autistic disorder: correlation with developmental regression. Ann Neurol 2007;62: S116-S117.

    Article  Google Scholar 

  49. Morris C. Maternal antibodies and placental-fetal IgG transfer theory. Totowa, NJ: Humana Press, 2008.

    Google Scholar 

  50. Singer HS. Serum anti-brain antibody differences in mothers of children with autism disorder: a study with fetal human and rodent tissue. International Meeting for Autism Research (IMFAR), 2007.

  51. Zimmerman AW, Connors SL, Matteson KJ, et al. Maternal anti-brain antibodies in autism. Brain Behav Immun 2007;21: 351–357.

    CAS  Article  PubMed  Google Scholar 

  52. Croen LA, Grether JK, Yoshida CK, et al. Maternal autoimmune diseases, asthma and allergies, and childhood autism spectrum disorders: a case-control study. Arch Pediatr Adolesc Med 2005;159: 151–157.

    Article  PubMed  Google Scholar 

  53. Chez MG, Dowling T, Patel PB, et al. Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. Pediatr Neurol 2007;36: 361–365.

    Article  PubMed  Google Scholar 

  54. Jander S, Schroeter M, Stoll G. Role of NMDA receptor signaling in the regulation of inflammatory gene expression after focal brain ischemia. J Neuroimmunol 2000;109: 181–187.

    CAS  Article  PubMed  Google Scholar 

  55. Purcell AE, Jeon OH, Zimmerman AW, et al. Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology 2001;57: 1618–1628.

    CAS  PubMed  Google Scholar 

  56. James SJ, Cutler P, Melnyk S, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 2004;80: 1611–1617.

    CAS  PubMed  Google Scholar 

  57. James SJ, Slikker W, 3rd, Melnyk S, et al. Thimerosal neurotoxicity is associated with glutathione depletion: protection with glutathione precursors. Neurotoxicology 2005;26: 1–8.

    CAS  Article  PubMed  Google Scholar 

  58. Chez MG. Superoxide dismutase overactivity, excessive selenium, and low copper in acquired epileptic aphasia (the Landau-Kleffner syndrome). Ann Neurol 1995;39: 544.

    Google Scholar 

  59. Beloosesky R, Gayle DA, Amidi F, et al. N-acetyl-cysteine suppresses amniotic fluid and placenta inflammatory cytokine responses to lipopolysaccharide in rats. Am J Obstet Gynecol 2006;194: 268–273.

    CAS  Article  PubMed  Google Scholar 

  60. Vezzani A. Inflammation and epilepsy. Epilepsy Curr 2005;5: 1–6.

    Article  PubMed  Google Scholar 

  61. Vezzani A, Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia 2005;46: 1724–1743.

    CAS  Article  PubMed  Google Scholar 

  62. Chez MG. Treatment of electroencephalographic epileptiform activity on overnight EEG studies in children with pervasive developmental disorder or autism: defining similarities to the Landau-Kleffner syndrome. J Dev Learning Disord 1998;2: 217–229.

    Google Scholar 

  63. Hollander E, Dolgoff-Kaspar R, Cartwright C, et al. An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry 2001;62: 530–534.

    CAS  Article  PubMed  Google Scholar 

  64. Plioplys A. Autism: electroencephalogram abnormalities and clinical improvement with valproic acid. Arch Pediat Adol Med 1994;148: 220–222.

    CAS  Google Scholar 

  65. Shenoy S, Arnold S, Chatila T. Response to steroid therapy in autism secondary to autoimmune lymphoproliferative syndrome. J Pediatr 2000;136: 682–687.

    CAS  Article  PubMed  Google Scholar 

  66. Sandler RH, Boite ER, Chez MG, et al. Relief of psychiatric symptoms in a patient with Crohn’s disease after metronidazole therapy. Clin Infect Dis 2000;30: 213–214.

    CAS  Article  PubMed  Google Scholar 

  67. Sandler RH, Finegold SM, Bolte ER, et al. Short-term benefit from oral vancomycin treatment of regressive-onset autism. J Child Neurol 2000;15: 429–435.

    CAS  Article  PubMed  Google Scholar 

  68. Boris M. Improvement in children with autism treated with intravenous gamma globulin. J Nutr Environ Med 2005;15: 169–176.

    CAS  Article  Google Scholar 

  69. Arts WF, Aarsen FK, Scheltens-de Boer M, et al. Landau-Kleffner syndrome and CSWS syndrome: treatment with intravenous immunoglobulins. Epilepsia 2009;50(Suppl 7): 55–58.

    CAS  Article  PubMed  Google Scholar 

  70. Mikati MA, Saab R. Successful use of intravenous immunoglobulin as initial monotherapy in Landau-Kleffner syndrome. Epilepsia 2000;41: 880–886.

    CAS  Article  PubMed  Google Scholar 

  71. Lewine JD, Andrews R, Chez M, et al. Magnetoencephalographic patterns of epileptiform activity in children with regressive autism spectrum disorders. Pediatrics 1999;104(3 Pt 1): 405–418.

    CAS  Article  PubMed  Google Scholar 

  72. Chez M. Practical treatment with pulse-dose corticosteroids in pervasive developmental disorder of autistic patients with abnormal sleep EEG and language delay. In: Perat M, ed. New developments in child neurology. Bologna, Italy: Monduzzi Editore, 1998.

    Google Scholar 

  73. Chez M. Pulse high-dose steroids as combination therapy with valproic acid in epileptic aphasia patients with pervasive developmental delay or autism. Ann Neurol 1998;44: 539.

    Google Scholar 

  74. Trauner D. Developmental aphasia with epileptiform abnormalities on EEG: clinical features and response to Prednisone. Ann Neurol 2002;52: 66–67.

    Article  Google Scholar 

  75. Lewine JD. Patterns of epileptiform activity and clinical response to steroid therapy in autism. International Meeting for Autism Research (IMFAR). Chicago, IL, 2009.

  76. Aykut-Bingol C. Pulse methylprednisolone therapy in Landau-Kleffner syndrome. J Epilepsy 1998;9: 189–191.

    Article  Google Scholar 

  77. Hempel A. Treatment of Landau-Kleffner syndrome with pulse dose prednisone: behavioral and language outcomes. Boston, MA: American Epilepsy Society Meeting, 2009.

  78. Stefanatos GA, Grover W, Geller E. Case study: corticosteroid treatment of language regression in pervasive developmental disorder. J Am Acad Child Adolesc Psychiatry 1995;34: 1107–1111.

    CAS  Article  PubMed  Google Scholar 

  79. Buitelaar JK, van Engeland H, de Kogel KH, et al. The use of adrenocorticotrophic hormone (4–9) analog ORG 2766 in autistic children: effects on the organization of behavior. Biol Psychiat 1992;31: 1119–1129.

    CAS  Article  PubMed  Google Scholar 

  80. Chez M. Effect of Lenalidomide on TNF-alpha elevation and behavior in autism. Presented at: International Meeting for Autism Research (IMFAR); May 20–22, 2010; Philadelphia, PA.

  81. Boris M, Kaiser CC, Goldblatt A, et al. Effect of pioglitazone treatment on behavioral symptoms in autistic children. J Neuroinflammation 2007;4: 3.

    Article  PubMed  Google Scholar 

  82. Brabers NA, Nottet HS. Role of the pro-inflammatory cytokines TNF-alpha and IL-1beta in HIV-associated dementia. Eur J Clin Invest 2006;36: 447–458.

    CAS  Article  PubMed  Google Scholar 

  83. Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration. J Neuroinflammation 2008;5: 2.

    Article  PubMed  Google Scholar 

  84. Deonna T. Reversible Behavioral autistic-like regression: a manifestation of a special (new?) Epileptic syndrome in a 28 month old child. A 2 year longitudinal study. Neurocase 1995;1: 91–95.

    Article  Google Scholar 

  85. Hollander E, Chaplin W, Soorya L, et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacol 2010;35: 990–998.

    CAS  Article  Google Scholar 

  86. Meador KJ, Baker GA, Browning N, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009;360: 1597–1605.

    CAS  Article  PubMed  Google Scholar 

  87. Posey DJ, Kern DL, Swiezy NB, et al. A pilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry 2004;161: 2115–2117.

    Article  PubMed  Google Scholar 

  88. King B. Double-blind, placebo-controlled study of amantidine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Psy 2001;184: 254–256.

    Google Scholar 

  89. Owley T, Salt J, Guter S, et al. A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. J Child Adolesc Psychopharmacol 2006;16: 517–524.

    Article  PubMed  Google Scholar 

  90. Chez MG, Burton Q, Dowling T, et al. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol 2007;22: 574–579.

    Article  PubMed  Google Scholar 

  91. Lafleur DL, Pittenger C, Kelmendi B, et al. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl) 2006;184: 254–256.

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

  1. Pediatric Neurology and Autism Neurodevelopmental Program, Sutler Neuroscience Institute, 95816, Sacramento, California

    Michael G. Chez

  2. Department of Neurology, University of California Davis School of Medicine, 95817, Sacramento, California

    Natalie Guido-Estrada

Authors
  1. Michael G. Chez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Natalie Guido-Estrada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael G. Chez.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Chez, M.G., Guido-Estrada, N. Immune therapy in autism: Historical experience and future directions with immunomodulatory therapy. Neurotherapeutics 7, 293–301 (2010). https://doi.org/10.1016/j.nurt.2010.05.008

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1016/j.nurt.2010.05.008

Key Words

  • Autism
  • immune therapy
  • immune dysfunction
  • autoimmunity